Many patients with type 2 diabetes mellitus have an increase in treatment escalation in order to achieve glycaemic targets over time, ultimately with a high proportion progressing to insulin-based therapy [4, 31]. This evidence concerns the gene INS and type 2 diabetes mellitus.